论文部分内容阅读
慢性肺源性心脏病(CCP)是指由于肺部、胸廓或血管的慢性病变所致的肺循环阻力增加,肺动脉高压(PAH)进而引起右心肥厚扩大甚至右心衰竭的心脏病。本病在我国较为多见,肺心病平均患病率为0.46%,患者多为老年人,具有反复发作、进行性加重等特点。近年来,肺心病的治疗取得了很大进展。本文就肺心病的氧疗、血管活性药物的运用、抗凝以及自由基的清除等方面的进展作如下综述。一、氧疗目前认为,缺氧是引起PAH的主要原因。缺氧时,某些介
Chronic Cor Pulmonale (CCP) refers to heart disease in which pulmonary vascular resistance (PAH) increases due to chronic lung, thoracic, or vascular pathologies, causing enlarged right ventricular hypertrophy and even right heart failure. The disease is more common in our country, the average prevalence of pulmonary heart disease was 0.46%, mostly elderly patients, with recurrent, progressive increase and so on. In recent years, the treatment of pulmonary heart disease has made great progress. This article reviews the progress of oxygen therapy for pulmonary heart disease, the use of vasoactive drugs, anticoagulation and the clearance of free radicals. First, oxygen therapy Currently that hypoxia is the main cause of PAH. Hypoxia, some mediated